摘要
目的观察酸味补肝汤对胆汁反流性胃炎小鼠的疗效,并探讨其作用机制。方法 KM小鼠60只,随机分为空白对照组,模型组,吗丁啉阳性对照组(3.9 mg·kg-1),酸味补肝汤高、中、低剂量组(19.8、9.9、4.95 g·kg-1),灌胃用药28 d后,以HE染色观察胃黏膜组织病理学改变,ELISA法检测血清白细胞介素8(IL-8)含量,免疫组化法检测胃黏膜环氧合酶2(COX-2)和核因子-κB p65(NF-κB p65)的表达。结果 HE染色结果显示,酸味补肝汤各剂量组能使模型小鼠的胃黏膜变薄、黏膜皱襞减少、炎细胞浸润等病理改变减轻;各剂量组小鼠血清IL-8含量均显著低于模型组(P<0.01);能不同程度地下调胃黏膜COX-2和NF-κB p65的表达。结论酸味补肝汤可使胆汁反流性胃炎小鼠胃黏膜组织得到改善和恢复,其作用机制可能通过抑制IL-8释放,下调COX-2和NF-κB p65表达,阻断致病因素对胃粘膜的慢性炎症损伤,从而对胆汁反流性胃炎起到治疗作用。
Objective To observe the effect of Suanwei Bugan decoction on bile reflux gastritis(BRG)mice and explore its mechanism.Methods Sixty KM mice were randomly divided into six groups:blank control group,model group,positive control group(domperidone,3.9 mg·kg-1),and Suanwei Bugan decoction high,medium,low dose groups(19.8,9.9,4.95 g·kg-1).After 28 days of gastric administration,HE staining was used to observe the histopathological changes of gastric mucosa,ELISA was used to detect serum IL-8 content,and immunohistochemical was used to detect the expression of COX-2 and NF-κB p65 in gastric mucosa.Results The results of HE staining showed that all doses of Suanwei Bugan decoction could reduce the pathological changes of gastric mucosa,plica of gastric mucosa and inflammatory cell infiltration.The serum IL-8 contents of all doses group mice of Suanwei Bugan decoction were significantly lower than that of the model group(P<0.01).The expression of COX-2 and NF-κB p65 in gastric mucosa could be reduced in different Suanwei Bugan decoction dose groups.Conclusion The gastric mucosa of BRG mice can be improved and restored by Suanwei Bugan decoction,and its action mechanism may be curing the chronic inflammation of gastric mucosa by inhibiting IL-8 release,reducing the expression of COX-2 and NF-κB p65,and blocking damage from the pathogenic factors.Therefore,it has therapeutic effect on BRG.
作者
宫健伟
李德芳
刘鲁英
冯国营
郑凤双
叶蕾
GONG Jianwei;LI Defang;LIU Luying;FENG Guoying;ZHENG Fengshuang;YE Lei(Binzhou Medical University,Yantai 264003 Shandong,China)
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2019年第7期802-805,共4页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
山东省中医药科技发展计划项目(2013-247)
